JanOne Earns US Patent for the Use of its Novel Formulation of Low-Dose Naltrexone, Jan123, to Treat Chronic Pain
Retrieved on:
Tuesday, August 29, 2023
LAS VEGAS, Aug. 29, 2023 /PRNewswire/ -- JanOne (Nasdaq: JAN), the visionary biotech company dedicated to discovering non-addictive treatments for pain, as well as causes of pain, has earned a US patent for its innovative formulation of low-dose naltrexone, Jan123, for treating pain.
Key Points:
- Jan123 is being developed to treat complex regional pain syndrome (CRPS), a rare and often life-altering condition characterized by severe pain and hypersensitivity to touch.
- "Today, patients with complex regional pain syndrome must resort to long-term opioid and narcotics for relief," Isaac said.
- Dr. Amol Soin, the inventor of Jan123 and its novel uses, expressed great satisfaction with the US Patent Office's action.
- "All in all," CEO Isaac concluded, "this patent approval is an important milestone in our company's brief history—and a welcome confirmation of our strategic vision."